```markdown
---
application_number: "214324Orig1s000"
applicant: "United Therapeutics Corp."
applicant_contact:
  name: "Sarah Gemberling, PhD, RAC"
  title: "Manager, Regulatory Affairs"
  address: "55 TW Alexander Drive, PO Box 14186, Research Triangle Park, NC 27709"
submission_date: "2021-04-16"
review_status: "Complete Response - Not Approvable"
proprietary_name: "Tyvaso DPI"
docket_number: "FDA-2021-P-0714"
review_completion_date: "2021-10-15"
regulatory_contact:
  name: "Brian Cooney"
  title: "Regulatory Project Manager"
  phone: "(301) 796-0886"
director_signature:
  name: "Norman L. Stockbridge, MD, PhD"
  title: "Director, Division of Cardiology and Nephrology"
  signed_date: "2021-10-15 17:02:13"
---

## Critical Data

| Field                            | Value                                                              |
|----------------------------------|--------------------------------------------------------------------|
| Application Number              | 214324Orig1s000                                                    |
| Drug Name                       | Treprostinil inhalation powder                                     |
| Proprietary Name                | Tyvaso DPI                                                         |
| Applicant                       | United Therapeutics Corp.                                          |
| Contact Person                  | Sarah Gemberling, PhD, RAC                                         |
| Submission Date                 | April 16, 2021                                                     |
| Review Status                   | Complete Response – Not Approvable                                 |
| Facility Classification         | Official Action Indicated (OAI)                                    |
| Safety Update Requirement       | Required per 21 CFR 314.50(d)(5)(vi)(b)                             |
| Labeling Status                 | Revisions Submitted; Further Comment Deferred                      |
| Proprietary Name Status         | Acceptable pending application approval                            |
| Citizen Petition Docket         | FDA-2021-P-0714                                                    |
| FDA Regulatory Contact          | Brian Cooney, (301) 796-0886                                       |
| Director                        | Norman L. Stockbridge, MD, PhD                                     |
| Signed Date                     | October 15, 2021, 05:02:13 PM                                      |

---

# CENTER FOR DRUG EVALUATION AND RESEARCH

## APPLICATION NUMBER:
214324Orig1s000

## OTHER ACTION LETTERS

**NDA 214324 COMPLETE RESPONSE**  
United Therapeutics Corp.  
Attention: Sarah Gemberling, PhD, RAC  
Manager, Regulatory Affairs  
55 TW Alexander Drive, PO Box 14186  
Research Triangle Park, NC 27709

Dear Dr. Gemberling:

Please refer to your new drug application (NDA) dated April 16, 2021, received April 16, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for treprostinil inhalation powder.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

---

## FACILITY INSPECTIONS

During a recent inspection of the for this application, our field investigator conveyed deficiencies to the representative of the facility. As a result of this inspection, FDA has classified this facility as Official Action Indicated (OAI) on for drug CGMP. Satisfactory resolution of these deficiencies is required before this application may be approved.

---

## PRESCRIBING INFORMATION

We acknowledge your email dated October 8, 2021 containing revised labeling. We reserve further comment on the proposed labeling until the application is otherwise adequate.

We encourage you to review the labeling review resources on:

- [Prescription Drug Labeling Resources](https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources)  
- [Pregnancy and Lactation Labeling Final Rule](https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule)

These include regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI)—a checklist of important format items from labeling regulations and guidances.

If you revise labeling, use the SRPI checklist to ensure that the Prescribing Information conforms with format items in regulations and guidances. Your response must include updated content of labeling [21 CFR 314.50(l)(1)(i)].

---

## CARTON AND CONTAINER LABELING

We reserve further comment on the proposed labeling until the application is otherwise adequate.

---

## PROPRIETARY NAME

Please refer to correspondence dated June 17, 2021 which addresses the proposed proprietary name, Tyvaso DPI. This name was found acceptable pending approval of the application in the current review cycle. Please resubmit the proposed proprietary name when you respond to the application deficiencies.

---

## SAFETY UPDATE

When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the product under consideration regardless of indication, dosage form, or dose level.

1. Describe in detail any significant changes or findings in the safety profile.
2. When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:
   - Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission.
   - Present tabulations of the new safety data combined with the original application data.
   - Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies described above.
   - For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.
3. Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified.
4. Provide case report forms and narrative summaries for each patient who died during a clinical trial or who did not complete a trial because of an adverse event. In addition, provide narrative summaries for serious adverse events.
5. Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original application data.
6. Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time).
7. Provide a summary of worldwide experience on the safety of this product. Include an updated estimate of use for product marketed in other countries.
8. Provide English translations of current approved foreign labeling not previously submitted.

---

## OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 314.110. If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 314.65.

You may also request an extension of time in which to resubmit the application.

A resubmission must:

- Fully address all the deficiencies listed in this letter  
- Be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter  
- Clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter

A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry:

> Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products

The drug product may not be legally marketed until you have been notified in writing that this application is approved.

---

## ADDITIONAL COMMENT

On July 8, 2021, Lassman Law + Policy submitted a citizen petition to FDA (Docket No. FDA-2021-P-0714) regarding the approvability of NDA 214324 for Tyvaso DPI. The issues raised by this petition are currently under review by the Agency, and FDA has not made a final decision on the issues the petition raises.

The deficiency comments included in this communication reflect only our current thinking, and this communication does not represent a final decision by the Agency on the issues raised in the pending citizen petition.

---

If you have any questions, please call:

**Brian Cooney**  
Regulatory Project Manager  
(301) 796-0886

Sincerely,  
Norman Stockbridge, MD, PhD  
Director  
Division of Cardiology and Nephrology  
Office of Cardiology, Hematology, Endocrinology, and Nephrology  
Office of New Drugs  
Center for Drug Evaluation and Research

---

> This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

**/s/**  
**Norman L Stockbridge**  
10/15/2021 05:02:13 PM  
Signature Page 1 of 1
```